Online Supplemental Material-Figure Legends

Supplemental Figure 1
1a: No significant changes in postprandial ApoB48 concentrations from baseline occurred following 6-weeks LC n-3 PUFA or 6-week placebo intervention periods in women with PCOS (n=22).
ApoB48, apolipoprotein B48; LC, long chain; PUFA, polyunsaturated fatty acids; PCOS, polycystic ovary syndrome. Data presented as means ± SD; Changes in postprandial ApoB48, as determined by change in AUC and iAUC from baseline following treatment with LC n-3 PUFA or placebo were as assessed by RM-ANOVA using change from baseline data controlling for supplement order.

1b: No significant changes in postprandial TAG concentrations from baseline occurred following 6-weeks LC n-3 PUFA or 6-week placebo intervention periods in women with PCOS (n=22).
TAG, triacylglycerol; LC, long chain; PUFA, polyunsaturated fatty acids; PCOS, polycystic ovary syndrome. Data presented as means ± SD; Changes in postprandial TAG, as determined by change in AUC and iAUC from baseline following treatment with LC n-3 PUFA or placebo were as assessed by RM-ANOVA using change from baseline data controlling for supplement order.

1c: Changes in postprandial NEFA concentrations at baseline, and following 6-weeks LC n-3 PUFA and placebo intervention periods in women with PCOS (n=22).
NEFA, non-esterified fatty acids; LC, long chain; PUFA, polyunsaturated fatty acids; PCOS, polycystic ovary syndrome. Data presented as means ± SD; Changes in postprandial TAG, as determined by change in AUC and iAUC from baseline following treatment with LC n-3 PUFA or placebo were as assessed by RM-ANOVA using change from baseline data controlling for supplement order. * indicates p-value <0.05 as assessed by independent t-tests of specific time-points.

Supplemental Figure 2
2a: No significant changes in postprandial glucose concentrations from baseline occurred following 6-weeks LC n-3 PUFA or 6-week placebo intervention periods in women with PCOS (n=22).
LC, long chain; PUFA, polyunsaturated fatty acids; PCOS, polycystic ovary syndrome. Data presented as means ± SD; Changes in postprandial TAG, as determined by change in AUC and iAUC from baseline following treatment with LC n-3 PUFA or placebo were as assessed by RM-ANOVA using change from baseline data controlling for supplement order.

2b: No significant changes in postprandial insulin concentrations from baseline occurred following 6-weeks LC n-3 PUFA or 6-week placebo intervention periods in women with PCOS (n=22).
LC, long chain; PUFA, polyunsaturated fatty acids; PCOS, polycystic ovary syndrome. Data presented as means ± SD; Changes in postprandial TAG, as determined by change in AUC and iAUC from baseline following treatment with LC n-3 PUFA or placebo were as assessed by RM-ANOVA using change from baseline data controlling for supplement order.
Supplemental Figure 1a:
Supplemental Figure 1b:
Supplemental Figure 1c:
Supplemental Figure 2a:
Supplemental Figure 2b: